Loading…
Loading…
Can you confirm, is that in the right ZIP code? And I'm just kind of curious if there's been any impact on the iTero manufacturing facility there.
Can you get squeezed in any way at the distributor level from the IRA price reductions
I'm kind of curious if you could just give us a little bit more details there and what's maybe driving that? Is it greater generic introductions or is it greater penetration
we're hearing concerns from investors that the lower-priced biosimilars could potentially have a negative impact on some of the profit pools in your specialty
I think what the market's kinda confused a little bit about is the deceleration, Jim, that we saw in that in the US segment from the September to the December
can you give us some color about how the quarter maybe played out sequentially
more than 1/3 of the oncology market that's clearly going to be impacted by either the IRA or a biosimilar transition
I'm just kind of curious if you're seeing anything that registers on on your radar screen positively or negatively heading into fiscal four q and fiscal twenty seven
the growth rate doubled in that geography. And so I'm trying to get a better sense of the stability of -- or I shouldn't say stability, the durability of that strength
boil it down a little bit for investors in terms of what you think the biggest opportunities are here over the next 12 months
you seemed to mention a path to mid-single-digit revenue growth, and I fully understand that is not where we are today
if we call it net $400 million of savings over the next three years, maybe for modeling purposes, if you could just sort of help us
is it fair to say that the first quarter will have the strongest growth, or you are saying no because it will be comparable versus restated numbers in 1Q 2025?